Opus Genetics opened lower at $4.23, compared with its previous close of $4.31. In the last trading session, the stock traded between $3.96 and $4.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Opus Genetics is now worth
$ 359.73
Giving a profit of
$ 259.73 (259.73%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.25 (-5.68%)
Day High
$4.35
Day Low
$3.96
Day Open
$4.23
Prev Close
$4.31
Volume
11,92,278
1W Return
-4.85%
1M Return
-12.52%
3M Return
4.88%
6M Return
-20.61%
1Y Return
106.35%
Fundamentals
Market Cap ($ Mn)
393
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-490.17%
ROCE
-204.87%
EPS (TTM)
$-0.10
Investment Returns
1 Week
-4.85%
1 Month
-12.52%
3 Months
4.88%
6 Months
-20.61%
9 Months
23.56%
Financials
Quarterly
All values in $ Mn
4.4
Mar 25
2.9
Jun 25
3.1
Sep 25
3.9
Dec 25
2.2
Mar 26
0.8
Jun 26
Updates
11Nov
RBC Capital raises Opus Genetics price target to $11, keeps Outperform
RBC Capital maintains Outperform rating on Opus Genetics. Price target raised to $11 from $9. Analyst Lisa Walter issued the rating update.
Yesterday
10Nov
Opus Genetics Q3 Results: Loss widens to $(0.46), revenue falls 63%
Opus Genetics posted a Q3 loss of $(0.46) per share, missing estimates by 206.67%. Quarterly revenue fell 63.07% YoY to $1.137 million against a $1.959 million forecast. Losses widened 84% compared to the $(0.25) per share loss in the prior year period.
2 days ago
5Nov
Opus Genetics completes dosing in Phase 1/2 trial for retinal disease therapy
Completed dosing in Cohort 2 of BIRD-1 trial with 11 participants. Dose increased three-fold to 4.5 × 10⁹ vg/eye compared to Cohort 1. Topline data expected in Q1 2027; Phase 3 dosing targeted for H2 2027. Aligned with FDA on pivotal endpoint involving microperimetry improvements.
7 days ago
3Nov
Opus Genetics grants 1.1 million stock options to new hires
Opus Genetics granted 1,100,000 stock options to ten new non-executive employees. Awards were approved under the 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4). Options vest over four years, with 25% cliff vesting after one year. Exercise price set at fair market value on the grant date.
10 days ago
16Oct
Opus Genetics wins FDA approval for presbyopia eye drop
FDA approved phentolamine ophthalmic solution 0.75% for adult presbyopia treatment. Approval triggers milestone payment from commercial partner Viatris Inc. Pivotal Phase 3 VEGA-2 and VEGA-3 trials met all primary and secondary endpoints. Condition affects approximately 90% of US adults over age 45.
27 days ago
16Oct
Opus Genetics presents gene therapy data, plans Phase 3 dosing
Opus Genetics presented clinical data for OPGx-BEST1 and OPGx-LCA5 at Retina in Rio 2026. OPGx-BEST1 showed improved retinal sensitivity in **75%** of evaluable participants in Cohort 1. OPGx-LCA5 demonstrated sustained visual improvements in adults through 24 months. Phase 3 clinical trial dosing for OPGx-LCA5 is expected in Q4 2026.
